DE69431480T2 - Imide als tnf alpha inhibitoren - Google Patents
Imide als tnf alpha inhibitorenInfo
- Publication number
- DE69431480T2 DE69431480T2 DE69431480T DE69431480T DE69431480T2 DE 69431480 T2 DE69431480 T2 DE 69431480T2 DE 69431480 T DE69431480 T DE 69431480T DE 69431480 T DE69431480 T DE 69431480T DE 69431480 T2 DE69431480 T2 DE 69431480T2
- Authority
- DE
- Germany
- Prior art keywords
- imide
- tnf alpha
- alpha inhibitors
- phthaloylisoglutamine
- phthaloylglutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8751093A | 1993-07-02 | 1993-07-02 | |
PCT/US1994/007411 WO1995001348A2 (en) | 1993-07-02 | 1994-07-01 | Imides as inhibitors of tnp alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69431480D1 DE69431480D1 (en) | 2002-11-07 |
DE69431480T2 true DE69431480T2 (de) | 2003-05-08 |
Family
ID=22205623
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69431480T Expired - Lifetime DE69431480T2 (de) | 1993-07-02 | 1994-07-01 | Imide als tnf alpha inhibitoren |
DE69434895T Expired - Fee Related DE69434895T2 (de) | 1993-07-02 | 1994-07-01 | Imide als Inhibitoren von TNF alpha |
DE69434645T Expired - Fee Related DE69434645T2 (de) | 1993-07-02 | 1994-07-01 | Aminen als Inhibitoren von TNF alpha |
DE69434029T Expired - Lifetime DE69434029T2 (de) | 1993-07-02 | 1994-07-01 | Verfahren zur Herstellung von Thalidomid |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434895T Expired - Fee Related DE69434895T2 (de) | 1993-07-02 | 1994-07-01 | Imide als Inhibitoren von TNF alpha |
DE69434645T Expired - Fee Related DE69434645T2 (de) | 1993-07-02 | 1994-07-01 | Aminen als Inhibitoren von TNF alpha |
DE69434029T Expired - Lifetime DE69434029T2 (de) | 1993-07-02 | 1994-07-01 | Verfahren zur Herstellung von Thalidomid |
Country Status (20)
Country | Link |
---|---|
US (1) | US5463063A (de) |
EP (5) | EP1477486A3 (de) |
JP (5) | JP3971794B2 (de) |
KR (1) | KR100401290B1 (de) |
AT (4) | ATE348809T1 (de) |
AU (1) | AU687843B2 (de) |
CA (3) | CA2626178A1 (de) |
CZ (2) | CZ294444B6 (de) |
DE (4) | DE69431480T2 (de) |
DK (4) | DK1004580T3 (de) |
ES (4) | ES2258956T3 (de) |
FI (2) | FI114984B (de) |
HK (3) | HK1025770A1 (de) |
HU (1) | HUT75312A (de) |
NZ (3) | NZ329258A (de) |
PL (1) | PL180377B1 (de) |
PT (4) | PT706521E (de) |
RU (1) | RU2174516C2 (de) |
SK (1) | SK166595A3 (de) |
WO (1) | WO1995001348A2 (de) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
CZ290372B6 (cs) * | 1994-12-30 | 2002-07-17 | Celgene Corporation | Imidy jako imunoterapeutická činidla a farmaceutický prostředek tyto imidy obsahující |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
DE19548378A1 (de) * | 1995-12-27 | 1997-07-03 | Bran & Luebbe | Verfahren und Gerätekombination zur Herstellung der Vergleichbarkeit von Spektrometermessungen |
EP0818439B1 (de) * | 1996-07-02 | 1999-10-13 | Nisshin Flour Milling Co., Ltd. | Imid derivate |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
NZ333903A (en) * | 1996-07-24 | 2000-02-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal |
EP2177517B1 (de) * | 1996-07-24 | 2011-10-26 | Celgene Corporation | Amino substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide zur Verringerung der TNF-Alpha-Stufen |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
EP1661566A3 (de) * | 1996-08-05 | 2008-04-16 | Myriad Genetics, Inc. | Verwendung von Beta-Blatt Mimetika als Protease und Kinase Hemmer sowie als Hemmer eines Transkriptionsfaktors |
EP0915700B1 (de) * | 1996-08-05 | 2006-03-22 | Myriad Genetics, Inc. | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors |
KR100539030B1 (ko) * | 1996-08-12 | 2005-12-27 | 셀진 코포레이션 | 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법 |
DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
ES2196592T3 (es) * | 1997-07-31 | 2003-12-16 | Celgene Corp | Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa. |
US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
DE69834668T2 (de) * | 1997-11-18 | 2007-01-11 | Celgene Corp. | Substituierte 2-(2,6-dioxo-3-fluoropiperidine-3-yl)-isoindoline und ihre Verwendung zum reduzieren des TNF-alpha spiegels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
TR200101501T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
DE19948126A1 (de) * | 1999-10-06 | 2001-04-12 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6670358B2 (en) * | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
ES2172474B1 (es) * | 2001-03-01 | 2004-01-16 | Fundacion Universitaria San Pa | Derivados de glutarimida como agentes terapeuticos. |
NZ531294A (en) * | 2001-08-06 | 2005-11-25 | Childrens Medical Center | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
AU2003234624B8 (en) * | 2002-05-17 | 2009-03-12 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
GB0215392D0 (en) * | 2002-07-03 | 2002-08-14 | Glaxo Group Ltd | Chemical compounds |
US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
US20060165649A1 (en) * | 2002-11-06 | 2006-07-27 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
CA2505131A1 (en) | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
JP2006510617A (ja) * | 2002-11-18 | 2006-03-30 | セルジーン・コーポレーション | (+)−3−(3,4−ジメトキシ−フェニル)−3−(1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−プロピオンアミドの使用方法およびそれを含む組成物 |
BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
JP2006519875A (ja) * | 2003-03-06 | 2006-08-31 | セルジーン・コーポレーション | 中枢神経系障害を治療するための選択的サイトカイン阻害剤 |
WO2004080422A2 (en) * | 2003-03-12 | 2004-09-23 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
CN100427465C (zh) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-烷基-异羟肟酸-异吲哚基化合物及其药物用途 |
US20060178433A1 (en) * | 2003-03-17 | 2006-08-10 | Yasuhito Yamamoto | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto |
CN100398534C (zh) * | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
CA2543132A1 (en) * | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
US20080213213A1 (en) * | 2004-04-14 | 2008-09-04 | Zeldis Jerome B | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
WO2005102317A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
EP1750697A4 (de) * | 2004-05-05 | 2009-08-26 | Celgene Corp | Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen |
WO2005112917A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
ITMI20041113A1 (it) * | 2004-06-01 | 2004-09-01 | Antibioticos Spa | Processo per la sintesi della talidomide |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
MX2007002521A (es) * | 2004-09-03 | 2007-05-09 | Celgene Corp | Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas. |
JP2008518924A (ja) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | 中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
PT2380887E (pt) * | 2005-06-30 | 2013-09-18 | Celgene Corp | Processos para a preparação de compostos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
GB0522460D0 (en) * | 2005-11-03 | 2005-12-14 | Prendergast Patrick T | Composition and method for the treatment of avian influenza |
EP2064193A1 (de) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterozyklische gpr40-modulatoren |
CA2662242C (en) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
CN101147743B (zh) * | 2006-09-19 | 2010-10-06 | 浙江海正药业股份有限公司 | 人参皂甙Compound-K在制药中的应用 |
CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
US7750048B2 (en) | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
WO2008130514A1 (en) | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
AU2008311355B2 (en) | 2007-10-10 | 2012-01-19 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
MX2010009654A (es) | 2008-03-06 | 2010-09-28 | Amgen Inc | Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. |
EP2358656B1 (de) | 2008-10-15 | 2014-01-01 | Amgen, Inc | Spirocyclische gpr40-modulatoren |
JP2012517441A (ja) | 2009-02-10 | 2012-08-02 | セルジーン コーポレイション | 結核の治療、予防及び管理のためのpde4モジュレーターの使用法及び含有組成物 |
MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
JP2013528206A (ja) | 2010-06-09 | 2013-07-08 | ジェネリクス・[ユーケー]・リミテッド | 結晶形態のサリドマイド及びその調製方法 |
AU2011268450B2 (en) | 2010-06-15 | 2015-07-16 | Amgen (Europe) GmbH | Biomarkers for the treatment of psoriasis |
GB201018171D0 (en) | 2010-10-28 | 2010-12-08 | Givaudan Sa | Organic compounds |
RS56770B1 (sr) | 2011-03-11 | 2018-04-30 | Celgene Corp | Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe |
US9809571B2 (en) | 2013-01-07 | 2017-11-07 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
US9790214B2 (en) | 2014-01-03 | 2017-10-17 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
WO2017006282A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
KR20180063895A (ko) | 2015-10-21 | 2018-06-12 | 오츠카 세이야쿠 가부시키가이샤 | 단백질 키나제 억제제로서의 벤조락탐 화합물 |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
CA3017740A1 (en) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
WO2018118947A1 (en) * | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
WO2019043214A1 (en) * | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
CN107698484B (zh) * | 2017-11-13 | 2020-05-19 | 广东中科药物研究有限公司 | 一种来那度胺的衍生物的制备方法与应用 |
CN110386893A (zh) * | 2018-04-17 | 2019-10-29 | 天津合美医药科技有限公司 | 异吲哚衍生物 |
PE20210184A1 (es) | 2018-07-11 | 2021-02-02 | H Lee Moffitt Cancer Ct & Res | Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon |
WO2020023782A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN112724024A (zh) * | 2021-01-19 | 2021-04-30 | 宁波酶赛生物工程有限公司 | 一种r-苄基苯乙胺的合成方法 |
WO2022187423A1 (en) * | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB768821A (en) * | 1954-05-17 | 1957-02-20 | Gruenenthal Chemie | Novel products of the amino-piperidine-2, 6-dione series |
GB1036694A (en) * | 1964-03-03 | 1966-07-20 | Wyeth John & Brother Ltd | Substituted aminocarboxylic acid derivatives and compositions containing such derivatives |
GB1030030A (en) * | 1964-12-28 | 1966-05-18 | Vismara Francesco Spa | Derivatives of phthalimide |
AT278739B (de) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Verfahren zur Herstellung von neuen Anhydriden und Imiden substituierter Dicarbonsäuren |
US3553217A (en) * | 1968-10-18 | 1971-01-05 | Aldrich Chem Co Inc | 2-(quinolinimido)glutarimide |
CH554837A (de) * | 1970-04-09 | 1974-10-15 | Ciba Geigy Ag | Verfahren zur herstellung von neuen (beta)-amino-(beta)-phenylpropionsaeuren, -estern und -amiden. |
CH554833A (de) * | 1970-04-09 | 1974-10-15 | Ciba Geigy Ag | Verfahren zur herstellung von neuen (beta)-amino-(beta)-phenylpropionsaeuren, -estern und-amiden. |
US4918193A (en) * | 1989-01-11 | 1990-04-17 | Burzynski Stanislaw R | Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion |
GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
-
1993
- 1993-10-20 US US08/140,237 patent/US5463063A/en not_active Expired - Lifetime
-
1994
- 1994-07-01 HU HU9600003A patent/HUT75312A/hu unknown
- 1994-07-01 PT PT94921439T patent/PT706521E/pt unknown
- 1994-07-01 AT AT00200491T patent/ATE348809T1/de not_active IP Right Cessation
- 1994-07-01 DE DE69431480T patent/DE69431480T2/de not_active Expired - Lifetime
- 1994-07-01 ES ES00200498T patent/ES2258956T3/es not_active Expired - Lifetime
- 1994-07-01 DK DK00200491T patent/DK1004580T3/da active
- 1994-07-01 EP EP04077075A patent/EP1477486A3/de not_active Withdrawn
- 1994-07-01 NZ NZ329258A patent/NZ329258A/xx not_active IP Right Cessation
- 1994-07-01 CZ CZ2003663A patent/CZ294444B6/cs not_active IP Right Cessation
- 1994-07-01 ES ES94921439T patent/ES2184765T3/es not_active Expired - Lifetime
- 1994-07-01 PT PT00200498T patent/PT1004572E/pt unknown
- 1994-07-01 CA CA002626178A patent/CA2626178A1/en not_active Abandoned
- 1994-07-01 AT AT00200498T patent/ATE319678T1/de not_active IP Right Cessation
- 1994-07-01 NZ NZ268812A patent/NZ268812A/en not_active IP Right Cessation
- 1994-07-01 DE DE69434895T patent/DE69434895T2/de not_active Expired - Fee Related
- 1994-07-01 AU AU72167/94A patent/AU687843B2/en not_active Ceased
- 1994-07-01 ES ES00200491T patent/ES2278574T3/es not_active Expired - Lifetime
- 1994-07-01 CA CA002166315A patent/CA2166315C/en not_active Expired - Fee Related
- 1994-07-01 DK DK00200492T patent/DK1004581T3/da active
- 1994-07-01 KR KR1019960700005A patent/KR100401290B1/ko not_active IP Right Cessation
- 1994-07-01 EP EP00200491A patent/EP1004580B1/de not_active Expired - Lifetime
- 1994-07-01 CA CA2531868A patent/CA2531868C/en not_active Expired - Lifetime
- 1994-07-01 EP EP94921439A patent/EP0706521B1/de not_active Expired - Lifetime
- 1994-07-01 EP EP00200492A patent/EP1004581B1/de not_active Expired - Lifetime
- 1994-07-01 NZ NZ329259A patent/NZ329259A/en not_active IP Right Cessation
- 1994-07-01 DK DK00200498T patent/DK1004572T3/da active
- 1994-07-01 PT PT00200491T patent/PT1004580E/pt unknown
- 1994-07-01 DE DE69434645T patent/DE69434645T2/de not_active Expired - Fee Related
- 1994-07-01 AT AT94921439T patent/ATE225344T1/de active
- 1994-07-01 EP EP00200498A patent/EP1004572B1/de not_active Expired - Lifetime
- 1994-07-01 DK DK94921439T patent/DK0706521T3/da active
- 1994-07-01 RU RU96102001/04A patent/RU2174516C2/ru not_active IP Right Cessation
- 1994-07-01 DE DE69434029T patent/DE69434029T2/de not_active Expired - Lifetime
- 1994-07-01 AT AT00200492T patent/ATE277036T1/de active
- 1994-07-01 CZ CZ9610A patent/CZ1096A3/cs unknown
- 1994-07-01 JP JP50364895A patent/JP3971794B2/ja not_active Expired - Fee Related
- 1994-07-01 PT PT00200492T patent/PT1004581E/pt unknown
- 1994-07-01 WO PCT/US1994/007411 patent/WO1995001348A2/en active IP Right Grant
- 1994-07-01 SK SK1665-95A patent/SK166595A3/sk unknown
- 1994-07-01 ES ES00200492T patent/ES2226696T3/es not_active Expired - Lifetime
- 1994-07-01 PL PL94312386A patent/PL180377B1/pl not_active IP Right Cessation
-
1995
- 1995-12-29 FI FI956362A patent/FI114984B/fi not_active IP Right Cessation
-
2000
- 2000-08-10 HK HK00104990A patent/HK1025770A1/xx not_active IP Right Cessation
- 2000-08-10 HK HK00104989A patent/HK1025769A1/xx not_active IP Right Cessation
- 2000-08-10 HK HK00104991A patent/HK1025765A1/xx not_active IP Right Cessation
-
2004
- 2004-04-27 FI FI20040593A patent/FI20040593A/fi not_active Application Discontinuation
-
2006
- 2006-02-16 JP JP2006039629A patent/JP2006131647A/ja active Pending
- 2006-02-16 JP JP2006039633A patent/JP2006188529A/ja active Pending
- 2006-02-16 JP JP2006039637A patent/JP2006188530A/ja active Pending
- 2006-02-16 JP JP2006039624A patent/JP4461107B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69431480T2 (de) | Imide als tnf alpha inhibitoren | |
ATE411029T1 (de) | Estrogene als antimitotika | |
DE69526206D1 (de) | Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit | |
DE69626513T2 (de) | Imidazolverbindungen | |
DE59608597D1 (de) | 4-acylaminopiperidin-n-oxyle | |
FI913142A (fi) | Migraenfoerhindrande alkoxipyrimidinderivat. | |
AP9100310A0 (en) | Tnf inhibitors | |
MY106956A (en) | Certain paf antagonist antihistamine combinations and methods. | |
DE69015270T2 (de) | Cyclische vinyloge N-hydroxy-N-methylharnstoffe verwendbar als 5-Lipoygenase-Inhibitoren. | |
DE69607167D1 (de) | Verbesserte zähigkeit und verarbeitbarkeit von polyolefinen und polyolefincopolymeren mit niedrigen molekulargewicht additiven | |
DE59105421D1 (de) | Mikrobiologische Oxidation von Ethylgruppen in Heterocyclen. | |
DE69517336D1 (de) | Verwendung schiefer implantation beim bilden der basis von bipolaren transistoren | |
NO903051D0 (no) | Anordning og fremgangsmaate for kompostering av kjoekkenavfall. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |